Clinical trial
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women…
NCT00099437 · AstraZeneca, Industry · Active, not recruiting
Key facts
| NCT number | NCT00099437 |
|---|---|
| Title | Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. |
| Official title | A Randomised, Double-Blind, Parallel-group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Fulvestrant (FASLODEX™) 250 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After… |
| Acronym | CONFIRM |
| Lead sponsor | AstraZeneca, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Fulvestrant |
| Enrollment | 736 |
| Start date | Feb 13, 2005 |
| Primary completion | Feb 27, 2009 |
| Completion | Dec 31, 2025 |
| First posted | Dec 14, 2004 |
| Last update posted | Sep 24, 2025 |
| Countries | Belgium, Brazil, Chile, Colombia, Czechia, Hungary, India, Italy, Malta, Mexico, Poland, Russia and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: